<DOC>
	<DOCNO>NCT01042977</DOCNO>
	<brief_summary>This study carry assess whether dapagliflozin improve glycemic control , decrease fast plasma glucose level , body weight blood pressure add patient 's exist medication compare usual treatment without added dapagliflozin . Safety data collect analysed confirm treatment dapagliflozin safe well tolerated patient diabetes cardiovascular disease</brief_summary>
	<brief_title>Efficacy Safety Patients With Type 2 Diabetes Mellitus Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Type 2 diabetes mellitus . Cardiovascular disease Uninterrupted antidiabetic treatment least 8 week enrolment Patients type 1 diabetes diabetes insipidus Patients 3 oral antihyperglycaemic drug without insulin and/or poorly control diabetes Any clinically significant illness , would compromise patient 's safety participation study</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>dapagliflozin</keyword>
	<keyword>diabetes</keyword>
	<keyword>cardiovascular disease</keyword>
</DOC>